HB 2437
In CommitteeHouse
Opioid treatment prg. fees
Establishing fee authority for accreditation services provided to opioid treatment programs by the department of health.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill lets the Washington State Department of Health apply to become the official accreditor of opioid treatment programs in the state, and to charge fees to cover the costs of that accreditation. If approved by the federal government, the Department will set fees and may use opioid settlement funds to help pay for the program.
- Authorizes the Department of Health to apply to the U.S. Department of Health and Human Services to become an approved accrediting body for opioid treatment programs under federal regulations (42 C.F.R. Part 8).
- If approved, the Department must follow federal policies and procedures and establish accreditation fees by rule, including an initial accreditation fee and a renewal fee.
- Requires that accreditation fees be set at levels sufficient to cover the full cost of providing accreditation services.
- Allows the Department to use money from the opioid abatement settlement account to help pay for accreditation-related expenses.
Who is affected
- Opioid treatment programs (OTPs) — Opioid treatment programs (OTPs) in Washington must pay fees to obtain or renew accreditation if the state becomes an approved accrediting body; these fees help cover the cost of the accreditation process.
- Washington State Department of Health — The state agency will gain authority to set and collect fees for accreditation services and may use opioid settlement funds to help cover related costs.
- Residents receiving opioid treatment — People receiving medication-assisted treatment for opioid use disorder may benefit from more consistent oversight and quality assurance through state-level accreditation.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (3)
State-level accreditation under federal oversight may improve consistency and quality assurance across OTPs, potentially enhancing treatment outcomes and reducing overdose risk for individuals with opioid use disorder.
Public SafetyPeopleRef: Sec. 1(1), Sec. 1(2)(a)Using opioid abatement settlement funds to cover accreditation costs helps ensure program sustainability without increasing reliance on general fund appropriations, preserving broader public health investments for treatment and recovery services.
HealthcarePeopleRef: Sec. 1(4)Fee-setting authority tied to full cost recovery ensures transparency and accountability in program administration, reducing risk of underfunding or inconsistent service delivery across regions.
HealthcarePeopleRef: Sec. 1(3)
Potential Concerns (2)
Opioid treatment programs (OTPs) must pay new or increased accreditation fees to maintain compliance, which could strain small, under-resourced OTPs—particularly those operating on tight margins or serving low-income populations—potentially leading to reduced service capacity or closures.
Business & EmploymentRef: Sec. 1(3)While using opioid settlement funds supports the program, diverting those funds toward administrative accreditation costs could reduce available resources for direct client services (e.g., outreach, harm reduction, counseling), especially in communities most affected by the opioid crisis.
Public SafetyPeopleRef: Sec. 1(4)
Who Is Most Affected
Small, community-based OTPs—especially those serving Medicaid patients or unhoused populations—may face financial pressure from new accreditation fees, potentially reducing service access in underserved areas.
State Department of Health gains operational authority and cost-recovery flexibility, but must balance administrative burden with equitable oversight—success depends on implementation rigor and resource allocation.
Patients in medication-assisted treatment may benefit from more standardized quality assurance, but could be harmed if fee-driven operational changes reduce program capacity or accessibility.
While settlement funds are used for accreditation, this may divert money from direct services like naloxone distribution, peer support, or housing assistance—critical components of recovery.
State and local governments may benefit from improved public safety outcomes and reduced emergency response/ER utilization if accreditation improves treatment outcomes—but only if OTPs remain viable.